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Overview
In some hospitals, far too many people get a treatment they 
should not get, even when the evidence is clear that it is 
unnecessary or doesn’t work. Australia urgently needs a system 
to identify these outlier hospitals and make sure they are not 
putting patients at risk.  
To show how such a system could work, this report examines five 
treatments that should not be used on certain patients. One is 
treating osteoarthritis of the knee with an arthroscope – putting a 
tube inside the knee to remove tissue. Another is filling a 
backbone (vertebrae) with cement to treat fractures. A third is 
putting patients in a pressurised oxygen chamber when it will not 
help treat their specific condition. 
Expert guidance labels most of these five treatments do-not-do, 
yet in 2010-11 nearly 6000 people – or 16 people a day – 
received them.  
These procedures can harm. Some people who had them 
developed infections or other complications during their hospital 
visit. Some could have avoided the stress, cost, inconvenience 
and risk of a hospital stay altogether. 
Do-not-do treatments happen in all states, cities and rural areas, 
in public and private hospitals. But the ones we measured only 
happen in a minority of hospitals, some of which provided do-not-
do treatments at 10 or 20 times the average rate.  
We also examined three procedures that are sometimes 
appropriate, but should not be offered routinely. Again, a few 
hospitals have very different treatment patterns from their peers. 
There are important reasons why clinicians sometimes choose 
inappropriate treatments. Evidence about treatments can be hard 
for clinicians to access, evaluate and use. Second, there is little 
systematic monitoring of where do-not-do treatments happen, 
leaving clinicians and hospitals in the dark about where problems 
might exist.  
Finally, the health system does not manage this problem well. 
There are rarely major negative consequences for providing 
ineffective care. In fact, there are incentives that go the other way 
– hospitals and clinicians get income for giving ineffective care. 
To fix the problem, the Australian Commission on Safety and 
Quality in Health Care should publish a list of do-not-do 
treatments. It should then identify public and private hospitals that 
provide these treatments more often than usual. There could be a 
good reason for a do-not-do treatment, but if some hospitals 
provide them consistently it is a real concern.  
These outlier hospitals should be asked to improve. If they do not, 
a clinical review by the state health department should check 
whether the hospital is providing the right care. If it is not, and if it 
still fails to improve, there should be consequences for the 
hospital’s management and funding.  
The approach in this report can easily be used for many more 
treatments, using evidence and data that governments already 
have. Governments should use the approach demonstrated in this 
report to make sure that far fewer people get the wrong treatment. 
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1. Finding questionable care
Quality health care involves correctly diagnosing a health 
problem, choosing the right treatment and delivering it effectively 
and safely. This report examines one part of quality care: 
preventing the wrong treatment from being chosen.  
Patients expect their treatment to be based on the best evidence 
about what works. But sometimes treatments are chosen that do 
not work, and may do harm, even when the evidence is clear. 
This report focuses on these choices. 
Getting the wrong treatment has serious consequences for 
patients. It puts their health at risk, wastes their time and, often, 
their money. It can even generate new health problems, while the 
original health problem may get worse.  
There are two signs that some patients are getting the wrong 
treatment. The first is that some treatments have been proven not 
to work but keep happening anyway. The second is extreme 
variation in patterns of care among hospitals. This suggests that 
in some places treatments are provided too often.1  
Both these ways to assess the effectiveness of care have merit, 
but also weaknesses. We combine them to create a new way to 
identify questionable care. 
                                            
1 Or that treatments are provided too rarely in some areas, as discussed further 
below. 
1.1 Ineffective treatments are hard to measure 
There is growing concern about treatments that don’t work. Once 
treatments become established, they often linger on, even after 
they have been disproven or discredited.2  
While no-one knows how much ineffective care is given, clinicians 
have raised the alarm for many years. A string of studies has 
found that evidence and clinical guidance are often not followed in 
Australia (Box 1).  
Unfortunately, ineffective care is hard to pin down. Few 
treatments are given that clearly don’t work for anyone. Typically, 
treatments are only proven not to work for a specific type of 
patient. Even then, the advice may be to not use the treatments 
routinely, rather than not at all.  
Another challenge is that the evidence on what doesn’t work can 
be unclear, out-of-date, low quality, or hard to find and interpret. 
Finally, there have been few convincing efforts to measure 
ineffective care across the health system, and it can be difficult to 
do so using existing data.  
  
                                            
2 This is demonstrated in Chapter 2. Chapters 3 and 6 discuss why ineffective 
treatments persist and outline some existing efforts to remove them. 
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Box 1: Inappropriate care in Australia 
Several studies have found that evidence and best practice 
guidelines are not always used to choose treatments. These 
studies look at different questions to this report. Our topic is 
unnecessary hospital treatments, but many of the studies look at 
under-provision, or at primary care. Nonetheless, they do suggest 
that there are real problems with clinical choices. For example: 
x A 2003-05 study audited Australian hospital emergency 
department management of community-acquired pneumonia, 
a condition that causes a significant amount of illness and 
death. It found that fewer than one in every five patients was 
treated in line with national guidelines.3  
x A 2005-08 survey examined GP treatment of lower back pain, 
a condition that cost more than $9 billion in Australia in 2010. 
It found that care regularly failed to match best practice 
recommendations, with high rates of patients receiving 
inappropriate imaging, specialist referrals, and medicines.4   
x A 2004-06 population survey examined adherence to national 
guidelines for lipid management, which is critical to the 
prevention of cardiovascular disease. It found that most high 
risk patients did not receive primary prevention, and that most 
of those who did were not achieving target lipid levels.5 
                                            
3 Maxwell, et al. (2005) 
4 Williams, et al. (2010) 
5 Janus, et al. (2010) 
1.2 Variation: an inconclusive warning 
The most striking fact about the large and extensively 
documented variations in patterns of medical practice, 
throughout the developed world, is the minimal impact this 
information has had on policy - Robert G. Evans6 
For decades, there has been concern about variation in health 
care. Why are people in some parts of the country up to five times 
more likely to get a tonsillectomy, for example? Does it mean 
some people are getting the wrong treatment? 
US research has found large, persistent variation in procedure 
rates for similar populations.7 There is less research in Australia, 
but significant variation has been found in surgery, diagnosis and 
prescribing.8 In all three areas, there is compelling evidence that 
clinician choices and availability of care, not just differences 
among patients and their health needs, drive the variation.  
There are large variations in rates of common surgical procedures 
in different parts of Australia. After standardising for age and sex, 
these rates sometimes vary by more than 12 times in different 
Medicare Local Areas (MLAs) (Figure 1).  
                                            
6 Evans (1990) 
7 US research finds high regional variation in hospital procedures and in tests, 
prescribing, primary care and elsewhere. Wennberg, et al. (1987); Phelps 
(1992); Burge, et al. (2000); Sepucha, et al. (2006); Filan, et al. (2007); Forte, et 
al. (2008); Morden, et al. (2012); Pham, et al. (2012); Birkmeyer, et al. (2013). 
8 Byles, et al. (2000); Australian Commission on Safety and Quality in Health 
Care (2013); Filan, et al. (2007); Hickie, et al. (1999); Barton, et al. (2006), p 322; 
Ilett, et al. (2010); Richardson (2001); Runciman, et al. (2012); OECD (2014). 
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Figure 1: There is great variation in how often procedures are given in different parts of Australia – a troubling but inconclusive finding 
 
Notes: Age and sex-adjusted rates of procedures in Medicare Local Area populations. CABG = Coronary Arterial Bypass Graft. All rates are standardized for age and sex.  
Source: Grattan Institute analysis of the National Hospital Morbidity Database (NHMD), 2010-11 
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This variation is dramatic and troubling. But while it hints at 
inappropriate care, it is difficult to interpret. Just because an area 
has a high rate of a treatment, it does not mean the rate is too 
high. Instead, people in other areas may be getting too few 
treatments.  
There are reasons why some variation is legitimate. Patients in 
different areas might have different health problems, more severe 
health problems, or different preferences about their treatment. 
Sometimes, there might be too little evidence to guide consistent 
choices.9  
The variation in Figure 1 is high enough to suggest that something 
is probably wrong. But to date, variation has been an inconclusive 
way to evaluate the quality of health care and has produced little 
policy action. An important reason is the lack of a convincing way 
to distinguish between legitimate and unwarranted variation.  
1.3 A new method: combine variation and ineffective care 
In the past, researchers have typically focused either on 
identifying ineffective treatments, or on variation among hospitals. 
To minimise the limitations of using variation and ineffective care 
separately, this report combines them to better identify troubling 
patterns of care. 
                                            
9 In line with the international literature, we found that variation was lower for gall 
bladder removal where evidence is relatively unambiguous (the extremal 
quotient, which is highest rate as a multiple of the lowest rate, is 2.2), than for 
tonsil removal (extremal quotient of 5.8). However, even the lower range 
indicated big differences in care. Variation is also higher in rural areas. See the 
methodological supplement for more detail on our findings. 
1.3.1 Variation 
The first step is measuring variation in how often a procedure is 
given. Figure 1 above follows the same approach used in most 
previous research, but for the rest of this report we make three 
improvements to the way variation is measured. Each helps to 
zero in on illegitimate variation. 
First, we measure variation among hospitals, rather than among 
geographic areas where patients live.10  
Second, we measure the rate of procedures only among relevant 
patients – people who have the disease the procedure is intended 
to treat. Many previous studies of variation measured how often 
patients in different hospitals got a particular procedure, such as a 
lumpectomy. Instead, we measure the rate of lumpectomies only 
among patients with breast cancer. This takes one of the big, 
legitimate causes of variation out of the equation. It means that a 
hospital will not seem to have an unusually high rate of 
lumpectomies simply because it has a large number of breast 
cancer patients.11  
The change makes a big difference. The hospital with the top rate 
using the crude measure (the rate among all patients) is different 
to the hospital with the highest rate using the new measure (the 
                                            
10 There are current debates about analysis of cost variation at the geographic 
level in the US, where state-level population health may legitimately determine 
most variation, see Sheiner (2014). However, our focus is on variation in clinical 
choices and on variation within as well as between states. 
11 Under the old approach, having an unusually large number of breast cancer 
patients would tend to result in a high lumpectomy rate. This is not the case after 
our adjustment. 
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rate among patients with malignant tumours). The two measures 
provide starkly different pictures of care. Most of the ten hospitals 
with the highest rates under the first measure are not among the 
top 10 under the second.12 
Just as we only compare relevant patients, we only compare 
relevant hospitals. If a hospital never gives a certain treatment, it 
might be because it doesn’t have the specialist doctors, 
equipment or facilities to do so. Or it might never see a patient 
with the relevant health condition. We are looking for variation 
caused by clinical choices, not by the specialisation of a hospital 
or the mix of patients it treats. 
For this reason, we only compare hospitals that provide the 
procedure we’re examining, and that also treat at least five 
patients with the relevant health problem each year.13  
1.3.2 Adding assessment of clinical effectiveness 
Despite all these improvements, variation still means different 
things for different types of procedures. That is where the 
effectiveness of a treatment comes into the picture. 
                                            
12 Our analysis of the National Hospital Morbidity Database showed that the top 
10 hospitals (by lumpectomy rate) for each measure are the same in only 3 
cases. Hospital rankings using each measure are only weakly correlated (0.48). 
The comparison only includes hospitals that perform lumpectomies. 
13 This helps ensure that hospitals with very few patients in the relevant group 
are not unfairly penalised (e.g. getting a 100% do-not-do rate for treating one 
patient). At least 1 procedure must be provided. For hyperbaric oxygen therapy 
at least 5 must be provided (see methodological supplement for discussion). 
If a treatment generally works, a hospital that provides it more 
often than others might be using it appropriately. If a treatment is 
proven to be ineffective, above-average rates are certainly a 
problem. For this reason, we look at variation in two kinds of 
procedures, based on the evidence about their effectiveness. 
The first are do-not-do treatments, which evidence shows should 
never be given to a specific type of patient. Variation can 
distinguish hospitals that provide these treatments rarely and 
hospitals that offer them more often. If a hospital only records a 
few do-not-dos, it could be due to data errors, or to a few 
extremely unusual patients. Where the treatments are more 
common, there is almost certainly a problem. 
The second category is do-not-do routinely treatments. 
Evidence shows they should not be given automatically to a 
specific type of patient. They should only be used for unusual 
patients, or if other options have failed or are inappropriate. Here 
variation is even more important. If a hospital provides the 
treatment much more than others do, some of its clinicians might 
have an unusual interpretation of ‘routinely’. 
Looking at patterns of care this way helps show where some 
treatments are highly suspect. It can never be perfect. It cannot 
capture all the complexity of clinical decisions. But it does provide 
useful new estimates about the appropriateness of care.  
The next chapter explains which procedures we looked at and 
what we found. The final chapters explain how to build on our 
approach to improve the quality of care.
Questionable care 
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2. Measuring questionable hospital care
2.1 Do-not-dos 
We started by looking for treatments that don’t work, drawing on 
lists of treatments that should not be given to certain kinds of 
patients, or to anyone.14 In some cases, clinical evidence has 
shown that the treatments do not work. In others, studies have 
failed to prove that they work. 
We drew on two academic studies and the work of two 
government advisory bodies (Box 2). Their advice about more 
than 1200 treatments was publicly available during the period 
covered by our data.15 However, limitations in the data released to 
us often meant we could not measure whether the advice was 
being followed (see the methodological supplement).  
Some advice was undermined by subsequent research, or it 
referred to treatments that only happened once or twice a year.16 
Some of the do-not-do recommendations from academic sources 
                                            
14 MSAC (1999d); ibid.; MSAC (1999a); MSAC (1999c); MSAC (1999b); MSAC 
(2000c); MSAC (2000a); MSAC (2001); MSAC (2002a); MSAC (2002b); MSAC 
(2003); MSAC (2004); MSAC (2005); MSAC (2006a); MSAC (2006b); MSAC 
(2007); NICE (2007c); NICE (2007b); NICE (2007a); MSAC (2008a); MSAC 
(2008b); MSAC (2008c); NICE (2010); Cassel and Guest (2012); Elshaug, et al. 
(2012); Prasad, et al. (2013). 
15 Findings published during or after our data period (2010-11) were not used.  
16 Four with insufficient volume were: therapeutic dilation and curettage for heavy 
menstrual bleeding, NICE (2007a); vagus nerve stimulation for epilepsy, MSAC 
(2008c); chemotherapy for patients with carcinoid heart disease; and lung 
transplants for cystic fibrosis, Prasad, et al. (2013). For the first two, there were 
no occurrences once legitimate uses were excluded, for the latter two there were 
only one or two a year. See the methodological supplement for more information. 
were based on relatively weak evidence. After we removed the 
do-not-do treatments in these categories, five remained.  
Many more do-not-do treatments could be measured by drawing 
on more sources and by using data that is available to 
government, but not available to us (see Chapter 7). 
Box 2: Sources for ineffective treatment list 
National Institute for Health and Care Excellence: (UK): NICE 
has produced do-not-do recommendations as part of an initiative 
to develop national evidence-based clinical guidance.  
Medical Services Advisory Committee (Australia): MSAC 
(which advises the Commonwealth Health Minister) has no 
explicit do-not-do list, but makes do-not-fund recommendations 
based on clinical and cost-effectiveness analysis of services that 
have, or are seeking, Medicare rebates.  
Prasad et al. (United States): researchers used studies from the 
New England Journal of Medicine to produce a list of 146 
treatments that were proven ineffective when new evidence 
contradicted previous research.  
We also used Elshaug et al. (Australia), but all the treatments 
we included were already covered in NICE guidance. It used 
published clinical evidence of potentially ineffective and/or unsafe 
non-pharmaceutical health services to produce a list of 156 low 
value health care practices.  
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As a final check, a panel of experienced clinicians reviewed our 
list for clinical relevance. The do-not-do treatments we focus on 
are:  
x vertebroplasty for osteoporotic spinal fractures: surgery to fill a 
backbone (vertebrae) with cement 
x arthroscopic debridement for osteoarthritis of the knee: 
inserting a tube to remove tissue 
x laparoscopic uterine nerve ablation for chronic pelvic pain: 
surgery to destroy a ligament that contains nerve fibres  
x removing healthy ovaries during a hysterectomy and 
x hyperbaric oxygen therapy (breathing pure oxygen in a 
pressurised room) for a range of conditions including 
osteomyelitis, cancer, and non-diabetic wounds and ulcers.17 
Expert evaluation has found that these treatments are ineffective, 
but the strength of the evidence varies. Well-designed studies 
show that arthroscopic debridement is no better than a placebo 
for osteoarthritis of the knee. By contrast, studies of hyperbaric 
oxygen therapy (for certain conditions) found no conclusive 
evidence of effectiveness, rather than conclusive evidence that it 
does not work.  
Nevertheless, we consider all five do-not-do treatments. None 
were supported by evidence. Four were listed as do-not-do 
                                            
17 MSAC (2000b); Moseley, et al. (2002); National Institute for Health and Care 
Excellence (2007a); National Institute for Health and Care Excellence (2007b); 
Kirkley, et al. (2008); Buchbinder, et al. (2009); Kallmes, et al. Ibid.; National 
Institute for Health and Care Excellence (2010). 
treatments by an expert government body.18 The other treatment, 
vertebroplasty, was listed as a do-not-do in Australia immediately 
after our data period, but this judgement was based on solid 
evidence published before 2010-11.19    
2.1.1 How many do-not-do treatments happen? 
All the do-not-do treatments we measure happen when a patient 
has a specific condition, such as knee osteoarthritis, and also gets 
a specific treatment, such as an arthroscopy, to remove tissue.20  
But some patients have a second health problem that could be a 
good reason for the treatment. As well as knee osteoarthritis, they 
could have a tear in their knee cartilage. An arthroscopy to treat 
osteoarthritis is a do-not-do treatment, but an arthroscopy to 
repair torn cartilage is considered appropriate.21  
In such cases we assumed that the arthroscopy was used to treat 
the tear – in other words, that it was legitimate. We applied many 
similar exclusions across most of our do-not-do treatments, ruling 
out more than 12,000 individual treatments. All the exclusions are 
listed in the methodological supplement.22  
                                            
18 By NICE and/or MSAC prior to the period we analysed.  
19 Buchbinder, et al. (2009); Kallmes, et al. Ibid.; MSAC (2011). 
20 Arthroscopic debridement, from this point we will simply use ‘arthroscopy’ as 
shorthand. 
21 Later evidence calls knee arthroscopy for meniscal tears into question, Khan, 
et al. (2014). All of our analysis is of clinical evidence available for the year we 
analysed, 2010-11, not the most recent available evidence. 
22 These exclusions and other coding were reviewed by an expert from the 
Victorian Department of Health. 
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Even looking at only five examples revealed a lot of potentially 
ineffective care. Nearly 6000 people a year, an average of 16 
people a day, get these treatments.23 Some do-not-do treatments 
happen more often. More than 4500 people a year get hyberbaric 
oxygen therapy when they do not need it. Others are rare: do-not-
do nerve ablation for pelvic pain happens just 35 times a year. 
These numbers alone do not describe the full extent of the 
problem. First, we only measured a tiny fraction of all do-not-do 
treatments. Much more do-not-do guidance is available. With the 
data they hold, Australian governments can measure many more 
of them than we can, as Chapter 7 explains in detail.24  
Second, among all the people getting hospital care, 6000 is a very 
small group. But among the people getting the five procedures we 
look at, it is a much bigger group. Four and a half per cent of 
patients getting these procedures should not have got them.25  
About one out of every 100 knee arthroscopies with debridement 
should not happen. A key element of specialist training is about 
choosing the right treatment. If even one per cent of treatment 
decisions are wrong, that is a big problem.  
For some other do-not-do treatments, the results are much worse. 
More than half of ovary removals during hysterectomy should not 
happen. One in four hyperbaric oxygen treatments should not 
happen, nor should one in every 20 vertebroplasties (Figure 3). 
                                            
23 5888 hospital visits (assumes individuals do not get multiple do-not-dos). 
24 We had access to only one data set – hospital inpatients – and could not link 
patients over time or admissions. 
25 As we only investigated selected do-not-do guidance, this is a lower bound; 
other guidance may classify more treatments as ‘do-not-do’. 
Figure 2: Do-not-do treatments in 2010-11 
 
Source: Grattan Institute analysis of NHMD 
Figure 3: A large share of some procedures happen to patients that 
should not get them 
 
Note: Guidance on ovary removal is about the procedure done with hysterectomy. Both the 
numerator and denominator here are for patients receiving both procedures. 
Source: Grattan Institute analysis of NHMD 
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Do-not-do treatments can hurt patients. Almost 150 patients who 
had a do-not-do treatment developed a new problem, such as an 
infection or a complication from surgical wounds, during their 
hospital stay. The overall rate is low (2.5 per cent) because knee 
arthroscopy and hyperbaric oxygen therapy are relatively safe and 
account for 93 per cent of the do-not-do treatments. Almost 14 per 
cent of patients getting the other treatments developed a new 
problem during their hospital stay.26  
The various do-not-do treatments also cost from $1300 to 
$4400.27 This money could be better spent on treatments that 
work and on reducing waiting lists. More than 1300 people had 
orthopaedic do-not-do procedures. At the same time, 7300 people 
on waiting lists were overdue for orthopaedic treatments.28 
2.1.2 Do-not-dos are in all states and both sectors 
We only look at a few do-not-do treatments, so we cannot make a 
general comparison among states. But it is clear that all states do 
too many do-not-do treatments and that different states have 
different problems (Figure 5). Comparing public and private 
hospitals is also inconclusive, but there are large differences for 
some treatments. Three of the do-not-do treatments – hyperbaric 
oxygen, vertebroplasty and nerve ablation – are more frequent in 
private hospitals by a large margin (Figure 4).  
                                            
26 These problems were not necessarily caused by the do-not-do treatment. 
27 Average public hospital costs for the highest- and lowest-cost do-not-do 
treatments. Estimates are for admissions that include a minimal number of other 
procedures. See the methodological supplement for further explanation. 
28 Extended wait orthopaedic patients at the time of the 2011 Census, Steering 
Committee for the Review of Government Service Provision (2014). Note that 
do-not-do and waiting list procedures may not be directly substitutable. 
The difference for vertebroplasty is mostly due to private hospitals 
in NSW and WA. NSW private hospitals give the treatment to 
around one in five compression fracture patients. In WA private 
hospitals, it is given to one in every four (Figure 6). These rates 
are 10 and 12 times higher than in other hospitals.29 Private 
hospitals in these two states account for nearly two-thirds (63 per 
cent) of all do-not-do vertebroplasties. On the other hand, public 
hospitals are 2.5 times more likely to do knee arthroscopies for 
osteoarthritis. 
Figure 4: Do-not-do rates vary by sector 
Public and private sector rates relative to national average (100%) 
 
Note: Categories are short-hand defined in text. Comparisons refer to rates among 
relevant patients. National avgs: 0.29%, 0.77%, 4.85%, 0.35% and 0.34%.  
Source: Grattan Institute analysis of NHMD 
                                            
29 21% and 25% of patients in NSW and WA private hospitals respectively. 
Comparison is with all other state-sectors: 2%. Sectoral comparisons only 
include states where we have private data: NSW, Victoria, Queensland, WA, SA. 
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Figure 5: Rates of do-not-do treatments vary by type and state, but all states have room to improve 
 
Note: Private hospital treatments are excluded for Tasmania and NT. ‘DND’ patients are patients for whom treatment is a do-not-do, e.g. for vertebroplasty, patients with compression fractures 
and no other condition for which vertebroplasty should be given. 
Source: Grattan Institute analysis of NHMD
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Figure 6: Most vertebroplasties are in NSW & WA private hospitals 
Share of vertebroplasties 
 
Source: Grattan Institute analysis of NHMD  
Figure 7: In almost all states, do-not-do treatments are 
concentrated in a minority of hospitals 
Proportion of public hospitals providing do-not-do treatments 
 
Source: Grattan Institute analysis of NHMD 
2.1.3 Do-not-do treatments happen in a minority of 
hospitals  
For public hospitals, we have separate data for each individual 
hospital (private hospital data were aggregated). While do-not-do 
treatments happen in all states, and in both cities and regional 
areas, they are highly concentrated in a minority of hospitals.  
Less than one fifth of public hospitals perform the do-not-do 
treatments we measure (Figure 7).30 The exception is the 
Northern Territory, which may simply reflect the fact that it has 
fewer hospitals than the other states we have data for.  
Strikingly, among the minority of hospitals that give these do-not-
do treatments, some give them far more often than others   
(Figure 8). 
For all the do-not-do treatments, the hospitals that perform the 
worst are a long way from the average. The do-not-do treatment 
with the lowest variation (compared to the average) is hyperbaric 
oxygen therapy. Even in this case, the worst hospital gives the do-
not-do treatment five times more often than average. 
For other do-not-do treatments, some hospitals are even further 
away from normal clinical patterns. Some hospitals provide the 
treatment at five or 10 times the national rate. One hospital gives 
arthroscopies for osteoarthritis 22 times more often than the 
national average. 
 
  
                                            
30 Hospital-level data was only available for public hospitals. 
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Figure 8: Some public hospitals give do-not-do treatments far more 
often than average 
Proportion of relevant patients that get a do-not-do treatment 
 
Note: Categories refer to specific procedure and patient-group pairs, see text or 
methodological supplement. 
Source: Grattan Institute analysis of NHMD 
2.2 Do-not-do routinely 
Few types of treatment are always wrong, even for patients with a 
specific health problem. We also analysed some treatments that 
should not be given routinely. They are: 
x fundoplication, in which the upper part of the stomach is 
wrapped around the bottom of the oesophagus (food pipe) to 
treat gastro-oesophageal reflux disease (stomach contents 
rising into the oesophagus) 
x episiotomy, a surgical cut made between the vagina and anus 
during labour for spontaneous vaginal births without 
complications and 
x amniotomy, an artificial rupture of membranes to augment 
labour during a normal delivery.31 
These treatments should not be given automatically, although 
they may be the best choice for some patients, such as those with 
unusual problems or conditions, or where other options have 
failed.  
Yet very high variation in how often these procedures are given 
suggests that some hospitals choose them much too often. 
Strikingly, women with spontaneous vaginal deliveries are almost 
three times more likely to have an episiotomy in the private sector. 
Patients with gastro-oesophageal reflux in South Australia are 
almost three times as likely to get fundoplication as people in 
other states. 
As with do-not-do procedures, some hospitals have very unusual 
patterns of care. The individual hospitals with the highest rates for 
                                            
31 NICE (2004); NICE (2007b). 
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the three do-not-do-routinely treatments offer them at twice, six 
times and nine times the average rate (Figure 9).  
Extremely unusual treatment choices can’t be blamed on the type 
of hospital or its location. Outlier hospitals come in many shapes, 
sizes and places.32 Just as with do-not-do procedures, they are in 
cities and in regional and remote areas (Figure 22). They are in 
most categories of hospital size and specialisation.33 In all these 
categories, outliers make up a small minority of hospitals.34  
Treatments that should not happen – and high rates of treatments 
that should not happen routinely – are in all states, in regional 
areas and cities, and in big and small hospitals. The good news is 
that for each do-not-do treatment, only a minority of hospitals 
have troubling patterns of care. The rest of this report shows what 
to do about these hospitals.  
The first step is providing better information about ineffective care 
and where it happens. This will help clinicians and hospitals 
interrogate their own patterns of care and act to improve them. 
When that does not solve the problem, we explain how to identify 
the most unusual patterns of care and subject them to an in-
depth, expert clinical review. 
                                            
32 As discussed below, for do-not-do treatments we label hospitals with above-
average rates outliers. For do-not-do routinely treatments we label hospitals that 
are in the top 10% in their comparator group outliers. Obviously, no statistical 
test would identify all hospitals above the average as outliers, but those hospitals 
do have concerning patterns of care. 
33 Outliers are in the largest three size quintiles and four scope (service diversity) 
quintiles. There is a skew towards bigger hospitals with diverse services, 
probably because we only look at three treatments (almost any small selection of 
treatments would be more prevalent in larger, less specialised hospitals). 
34 Less than 20% of any size or scope quintile. 
Figure 9: Outlier public hospitals provide do-not-do-routinely 
treatments far more often than their peers 
Proportion of relevant patients getting do-not-do-routinely procedure 
 
Note: Categories refer to procedure and patient-group pairs, see text. Outliers are the 10% 
of hospitals with the highest rates of do-not-do-routinely treatments, see text. 
Source: Grattan Institute analysis of NHMD 
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Figure 10: Do-not-do routinely treatments vary by state and sector 
Proportion of relevant patient group getting do-not-do routinely treatment 
 
Source: Grattan Institute analysis of NHMD 
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3. Stopping the wrong choices
New efforts to cut the use of ineffective treatments – sometimes 
known as disinvestment – are starting to appear. Yet good 
evidence is lacking about which approaches work best.35 This is 
partly because formal disinvestment policies are still in their 
infancy in Australia and around the world. It is also because  
attempts to stem ineffective care have met many challenges.  
Perhaps the greatest of these is the health system’s focus on 
adding new treatments and doing more. The system pays little 
attention to removing old treatments and doing less. There are 
also many other barriers, ranging from technical problems to 
cultural issues (Box 3). 
This wide range of barriers reflects the many influences on the 
treatment choices that clinicians make. Health care workers are 
driven by their training, professional culture and beliefs, and their 
desire to help patients.36 They are also influenced by 
organisational practices and culture, by financial incentives and by 
government policy (Figure 11).37 These factors will be more or 
less important in different hospitals and clinics, and for different 
individuals.  
                                            
35 Gallego, et al. (2010) 
36 A US study measured determinants of regional Medicare spending and found 
that physician beliefs (not supported by evidence) were the most important 
factor, Cutler, et al. (2013). Doust and Del Mar (2004) point to a range of 
reasons that an individual clinician may choose an ineffective treatment 
including: a need to do something, real or perceived patient expectations, and 
over-reliance on surrogate outcomes. 
37 Zezza, et al. (2014)  
Because of this complexity, many experts in health care 
improvement recommend tailoring responses to specific barriers 
in different organisations.38 There is no conclusive evidence that 
tailored solutions are better, yet it seems safe to assume that a 
single set of operational solutions won’t work everywhere.39  
Box 3: Some obstacles to current disinvestment efforts 
x Inertia and failure to acknowledge that current practices aren’t 
working 
x Unclear objectives of disinvestment efforts 
x Lack of clear processes or incentives to sustain change  
x Limited resources and commitment from policy-makers, 
funders and clinicians 
x Difficulty identifying when disinvestment is happening because 
guidance is vague or cannot be measured with existing data  
x Political resistance due to patient and clinician opposition and 
media interest 
Sources: Elshaug, A.G. et al. (2009); Haas et al. (2012); Schmidt (2012); Queensland 
Health (2013). 
                                            
38 Grol and Grimshaw (2003); Grol and Wensing (2004). 
39 A Cochrane review found no conclusive evidence that tailored strategies are 
superior, Baker, et al. (2010). Evidence is mixed on efforts to improve the 
appropriateness of care in general, Shojania and Grimshaw (2005); Scott (2009). 
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Accordingly, rather than propose a specific, universal solution, this 
report focuses on the overarching incentives and information that 
health care providers need to stop ineffective care. In other words, 
we focus on the outermost bubble in Figure 11: the financial, 
regulatory and policy context.  
Devolution – self-management by hospital networks – can work 
well if the system has clear objectives, and if hospital networks 
have clear incentives and accountability to meet them. 
Getting the broader context right can prompt a wide range of 
local, tailored solutions. These could range from changes in 
training, staffing and performance management to changes in 
technology, work-flow and role design.40 These changes should 
ultimately produce a self-sustaining culture that refuses to accept 
ineffective care.  
To get there, we must first tackle three serious problems that are 
evident in the wider financial, regulatory and policy context:  
x information about what constitutes an ineffective treatment is 
diffuse, often low-quality and hard to use 
x there is not suitable information about variation in hospital 
performance to focus efforts where performance is worst and 
x there are financial incentives to provide ineffective care and 
the incentives not to provide ineffective care are too weak. 
                                            
40 Approaches to implementing change are discussed in Grol, et al. (2013). For 
an example of a tailored approach to reducing unnecessary ankle radiographs in 
an Adelaide hospital see Bessen, et al. (2009). 
The following three chapters discuss each of these issues in turn. 
 
Figure 11: Barriers and enablers of change at different levels 
 
Source: Adapted from Grol and Wensing (2004) 
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4. Identifying ineffective treatments
Many hospitals, states and national bodies in Australia and 
overseas have started some kind of disinvestment effort. But 
current approaches aren’t working well enough. They are 
fragmented and inconsistent, some fail to draw on sufficient 
clinical expertise, and recommendations often sit on the shelf 
instead of improving clinical choices. 
The many organisations working on disinvestment in Australia 
include ministerial advisory councils, government health 
departments,  statutory authorities, hospital networks, private 
hospitals and specialist medical colleges.41 
These efforts aren’t just diffuse, they are uncoordinated. At 
present multiple organisations might assess the effectiveness of 
the same treatment. This wastes time, effort and resources and 
could lead to conflicting guidance to clinicians.  
In addition, these evaluations are typically ad hoc and 
opportunistic. There are many approaches, but no clear standard 
of how to define and identify disinvestment.42 In particular, it is not 
clear how treatments are chosen for assessment.43 
                                            
41 For example, the Commonwealth Government’s Safety, Quality and 
Sustainability Forum, the Health Policy Advisory Committee on Technology (part 
of an Advisory Council for Australian health ministers), clinical senates in 
Queensland and South Australia, projects in state health departments and 
Monash Health in Victoria.  
42 Although some systems have attempted to establish a standard approach e.g. 
NICE in the UK and the Basque health system, Ibargoyen-Roteta, et al. (2010). 
43 Gallego, et al. (2010) 
Getting the right approach is both important and difficult. It 
requires assessing evidence on safety, clinical effectiveness and 
feasibility. It requires overcoming limited expertise about 
disinvestment and dealing with gaps in evidence and data. 
Clinical expertise is crucial to get the analysis right and make it 
credible. Yet clinician involvement in identifying ineffective care 
varies. The fragmented system risks spreading medical colleges 
and other expert bodies very thin, or not including them at all.44  
The government has recently announced a comprehensive review 
of services funded by Medicare. This is welcome and could 
address many of the problems outlined above. But because 
evidence keeps changing, and new treatments keep emerging, 
we also need an ongoing system to evaluate which treatments do 
not work, and to let people know about it.  
4.1 Streamlined governance  
The Australian Commission on Safety and Quality in Health Care 
(the Commission) should do two things to combat ineffective 
care.45 First, it should streamline the process by which do-not-do 
                                            
44 In broader efforts that go beyond clinically ineffective care (targeting over or 
under-servicing) consumer involvement is also critical, discussed below. 
45 If it is established, the Health Productivity and Performance Commission, a 
new body proposed in the 2014 Commonwealth Budget, would be in a good 
position to take on this role instead. Subject to consultation the HPPC was 
intended to absorb several agencies including the Australian Commission on 
Safety and Quality in Health Care, Dutton and Cormann (2014). 
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treatments are identified and communicated to health 
professionals. Second, wherever possible, it should monitor and 
reveal where do-not-dos are still happening. In these roles, the 
Commission will be most effective if both the Commonwealth and 
states can guide its work. 
4.2 Picking or choosing? 
When it comes to finding out which care is ineffective, the 
Commission has three possible roles. It could coordinate the work 
of other bodies, it could actively evaluate work done elsewhere, or 
it could be responsible for the entire analysis (Figure 12).  
These options range from bottom-up (influencing and coordinating 
other efforts) to top-down (deciding where to look, how to look, 
and finding the answers). The top-down approach is closer to the 
UK’s National Institute for Health and Clinical Excellence (NICE).  
The bottom-up approach is closer to the Choosing Wisely 
campaign, which is run by the American Board of Internal 
Medicine. The campaign provides information on treatments that 
“clinicians and consumers should question”. In 2015, Australia 
began its own Choosing Wisely campaign, with five medical 
colleges recommending that a total of 27 interventions be 
questioned.46 These two approaches are discussed in Box 4. 
Each approach has benefits and drawbacks (Figure 13). A top-
down model would provide the most consistent, objective, 
transparent and relevant evaluation. Yet it would also need the 
biggest funding commitment and may be resisted by 
                                            
46 See http://www.choosingwisely.org.au/. 
organisations that do disinvestment evaluations now. As a starting 
point, we recommend a coordination and evaluation role. The 
Commission would guide, validate and promote guidance 
developed elsewhere. 
Figure 12: Identification of do-not-dos can be bottom-up or top-
down 
Diagram of possible do-not-do identification roles  
 
Source: Grattan Institute 
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Box 4: Examples of top-down and bottom-up approaches: 
NICE do-not-dos and Choosing Wisely 
England’s National Institute for Health and Care Excellence 
(NICE) provides national guidance and advice to improve health 
and social care. That includes assessing health technology and 
recommending whether it should be funded in the National Health 
Service. NICE has been an independent public body since 2013. 
As a spin-off from its guidance development, NICE has developed 
a list of more than 1000 do-not-do recommendations.47 These are 
based on expert NICE reviews of evidence, with input from 
clinicians and the community. 
The American Board of Internal Medicine, which certifies a quarter 
of US physicians, launched Choosing Wisely in 2012. The 
campaign, since repeated in Canada, Italy and here, promotes 
conversations between providers and patients about ineffective or 
unnecessary care. They publish “things providers and patients 
should question” and aim to influence clinician and patient 
attitudes rather than immediately changing funding or behaviour.48  
Fifty-nine US national organisations representing medical 
specialists, plus consumer groups, have partnered with ABIM to 
identify more than 300 ineffective or unnecessary practices. 
The do-not-do recommendations of both NICE and Choosing 
Wisely depend on robust evidence and input from specialist 
medical and surgical colleges. The analysis in this report drew on 
both. 
                                            
47 Probably the most developed disinvestment model, Gallego, et al. (2010). 
48 ABIM Foundation (2013); Wolfson, et al. (2014). 
Box 5: Disinvestment evaluation should be: 
x accountable – stakeholders are responsible for meeting 
defined standards and improving outcomes (quality of care 
and patient outcomes, for example) within their realm of 
responsibility and influence 
x consistent – standardised processes apply to all 
stakeholders, including clinicians, consumers, medical 
societies, hospitals, funders, policy-makers 
x efficient – waste and unnecessary duplication are avoided 
x objective – the process is evidence-based and without bias, 
for example it minimises conflicts of interest and other biases 
x responsive – it addresses the information needs of decision 
makers, including clinicians, consumers and funders;  
x rigorous – it minimises bias and creates reproducible results; 
x transparent – it contains ongoing assessment and reporting 
against goals, strategies, outcomes and budgets so observers 
can easily link judgments, decisions or actions to relevant data 
and 
x feasible – it is likely to work in the real world (recognises 
social, fiscal, political and economic constraints). 
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Figure 13: Different roles have different benefits and drawbacks 
Commission roles measured against principles of evaluation (see Box 5) 
 
Status 
quo Coordinate Coordinate & evaluate Initiate 
Accountability Low Low Mid-high Mid-high 
Consistency Low Low Mid-high High 
Efficiency Low Mid Mid-high Mid-high 
Objectivity Low Mid Mid-high High 
Responsiveness Low Mid Mid-high High 
Rigour Low Low Mid-high Mid-high 
Transparency Low Low Mid-High High 
Feasibility High High Mid Low 
 
Sources: Grattan Institute, adapting a framework and findings from Sox et al. (2008). 
 
 
In order to identify ineffective care, the Australian Commission on 
Safety and Quality in Health Care should: 
x Publish a do-not-do list after checking that the underlying 
quality of studies and evidence is adequate, and following 
input from clinicians and experts 
x Set do-not-do research priorities in consultation with clinicians, 
funders and consumers and encourage work in these areas 
x Reduce duplication by publishing a list of ongoing 
disinvestment research by other bodies  
x Codify and promote best practices in identification of 
ineffective care 
x Coordinate an Australian Choosing Wisely campaign, where 
medical colleges identify low-value treatments for 
disinvestment. 
This approach will still allow other organisations to identify 
ineffective treatments. However, the Commission will test the 
quality of that work, promote research where it is most needed 
and reduce duplication across the system.  
Identification of ineffective care leads to the second part of the 
Commission’s role: letting people know which care is ineffective 
and where it is happening. This is discussed in the next chapter.  
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5. Providing better information
The complexity of modern medicine exceeds the inherent 
limitations of the unaided human mind 
David M. Eddy, MD, Ph.D 
To stop ineffective care, it’s crucial to know which treatments don’t 
work, where they happen, and where levels of treatments seem 
too high. But that information is hard to come by. Guidance for 
clinicians is scattered and hard to use, and no one systematically 
tracks and reports on care that is likely to be ineffective. 
5.1 Clear guidelines on what not to do 
Clinicians find out about which treatments work – and which don’t 
– from many different places. These include their training and 
ongoing education, academic journals, colleagues, and clinical 
guidelines. No single system should try to replace all these 
sources of knowledge. Yet the persistence of ineffective care 
suggests that they are not working well enough. 
It is hard to keep up with the vast volume of medical evidence. 
Reading all the journal articles relevant to primary care would take 
more than 20 hours a day, according to one estimate from 2002.49 
Another study found that half the evidence published about 
nephrology (kidneys) was spread across 20 journals, with the rest 
published in 1428 other publications.50 And the volume of 
evidence keeps growing (Figure 14).  
                                            
49 Alper, et al. (2004) 
50 Garg, et al. (2006) 
It isn’t possible to read all the relevant material, let alone critically 
evaluate its quality. Instead, clinicians must often rely on 
systematic reviews (which are themselves growing exponentially) 
and particularly on clinical guidance – expert interpretations of the 
evidence and what it means for clinical practice. 
Unfortunately, clinical guidance is often a poor way to find out 
which treatments don’t work. It tends to focus on what should be 
done, not what should be avoided. Clinical guidance can also be 
very hard to keep track of. It is produced by a dizzying array of 
organisations: at least 41 government entities plus medical 
colleges, groups for specific health conditions and specialty 
societies.51  
Guidelines can be difficult to use, often running to hundreds of 
pages.52 Their quality is also uneven. In an evaluation of 
Australian guidelines from 2005 to 2013, fewer than half met basic 
standards such as having a clear intended audience, a clear 
setting (such as GP clinic or hospital) and a clear process for how 
a guideline was developed (Figure 15).  
                                            
51 National Health and Medical Research Council (2014). There are also other 
forms of guidance, such as factsheets, developed and distributed by yet more 
organisations. 
52 For example, the NHMRC Type 2 diabetes  guideline developed by the 
Diabetes Australia Guideline Development Consortium has 935 pages, Bayram, 
et al. (2009). 
Questionable care 
Grattan Institute 2015 23 
Figure 14: The volume of medical evidence is huge and growing 
Articles indexed in Medline (PubMed), total and with selected terms in 
the title, 1994-2013 
 
Source: Grattan Institute analysis of Corlan (2004) 
Figure 15: Clinical guidelines often fail measures of quality 
 
Note: Assessed guidelines published from 2005-2013 (n = 1,046). 
Source: National Health and Medical Research Council (2014) 
There is also little evidence on how guidelines are used or their 
impact. Given all these problems it is worth making them much 
easier to use.53 A clear, concise list of ineffective treatments 
would be a good start.  
We recommend that the Australian Commission on Safety and 
Quality in Health Care publishes up-to-date do-not-do lists. They 
should be organised by disease, specialty and site of care. 
Importantly, the Commission should review them at least every 
two or three years.54 Much of the guidance we looked at had not 
                                            
53 National Health and Medical Research Council (2014). 
54 García, et al. (2014) found that almost one in five recommendations in clinical 
guidelines are out-of-date after three years (18.7%). 
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been revised in many years, even though the evidence has 
changed substantially.55  
A clear list, from an authoritative source, would be a one-stop-
shop for information about ineffective care. The lists would assist 
everyone who provides health care, particularly GPs and other 
people who treat many different kinds of health problem.56 
Clinicians, hospitals, clinics, training organisations and 
professional bodies could use these central lists to help improve 
the quality of health care. The Australian Commission on Safety 
and Quality in Health Care could encourage organisations that 
develop guidelines to include the do-not-do recommendations, 
preferably in a separate section for easy reference.  
5.2 Reporting on performance 
Yet even when information is readily available in one place, it 
won’t always be used. When ineffective care keeps happening 
despite clear guidance, clinicians, hospitals, policy-makers and 
funders need to know so that they can take action. Not all types of 
ineffective care can be easily measured. Yet the Commission can 
start by building on the approach we have used.  
Using our approach, the Commission should report on rates of do-
not-do and do-not-do-routinely procedures to all organisations that 
fund care (the Commonwealth, States and private insurers) and to 
accreditation bodies.  
                                            
55 As discussed in the methodological supplement, this resulted in our 
abandoning analysis of several ‘do-not-do’ procedures. 
56 Much do-not-do guidance is for primary care, so not analysed in this report. 
More importantly, reports should go to each hospital network. 
Without objective performance measures, over-confidence can 
stop poor quality care from being acknowledged. Some hospital 
boards clearly suffer from over-confidence. A large majority of 
Victorian board members think the care in their hospital is above 
the average of other Victorian hospitals, which is simply 
impossible (Figure 16).57 
Figure 16: Most Victorian hospital network boards think they are 
better than average 
Proportion of board members 
 
Notes: Victorian 2012 survey, n = 233, 70% response rate, 96% of boards represented. 
Source: Bismark et al. (2013) 
                                            
57 The  “above average effect”, or “illusory superiority”, is a well-known cognitive 
bias, Dunning, et al. (2003), popularised through by Garrison Keilor (1985) as 
the ‘Lake Wobegon’ effect Keillor, G. (1985) Lake Wobegon days, Viking. 
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Medical colleges should also be told about the questionable care 
that their members provide in different hospitals. The colleges can 
use this to inform accreditation of hospital training programs and 
in their training and quality improvement programs. 
The Commission might also choose a slightly less conservative 
way to measure questionable care than the one we use. Using 
expert clinical guidance, we exclude all patients with a problem 
that could possibly be effectively treated by the do-not-do 
procedure.58 This cuts the risk of false positives: mistakenly 
calling effective care a do-not-do.  
At the same time, it raises the risk of false negatives: not picking 
up some ineffective care. But we have chosen this approach 
because it is more generous to clinicians and less likely to give 
hospitals an unfair, negative evaluation. Our goal is to make any 
change more widely-accepted and effective. The risk is that it 
could let some ineffective care slip through undetected. It would 
also be easier to game by changing how patient health problems 
are recorded.59 There is no single right answer. Either approach 
would be an improvement, bringing more ineffective care to light. 
Other ways to make information about ineffective care easy to use 
include summarising it in checklists and electronic decision 
support systems, which are a promising way to improve care (see 
Box 7).60  
                                            
58 In Chapter 2, we give the example (a patient with a meniscal tear and knee 
osteoarthritis). Our screen also looked for procedures that could legitimate the 
do-not-do treatment. See the methodological supplement for more information. 
59 See the discussion of funding cuts for the knee arthroscopy do-not-do below. 
60 Gawande (2010) 
This report doesn’t present or evaluate all the options. We focus 
on the first step: the Australian Commission on Safety and Quality 
in Health Care should clarify which treatments are ineffective, how 
much they happen, and where they happen. Health care 
organisations and professionals can then use this information to 
eliminate treatments that don’t work.  
Box 6: Information for patients 
In this chapter we recommend giving information on ineffective 
care to hospitals, clinics, health care professionals and medical 
colleges. We don’t suggest informing patients directly, although a 
list of ineffective care could be publicly available on the Australian 
Commission for Safety and Quality in Health Care’s website.  
Providing information to patients can be beneficial.61 Yet this 
report focuses on treatments that should never be chosen. We 
believe that health care providers, not patients, should be 
responsible for avoiding this kind of ineffective care. Do-not-do 
advice may also be difficult for patients to interpret. 
By contrast, it may be worthwhile informing patients about 
variation in patterns of care. This is discussed in the next chapter.  
Patients and their advocates should be involved in the 
Commission’s work identifying ineffective care. 
                                            
61 Evaluating the impact of providing information to patients is beyond the scope 
of this report. However, there is evidence that clinician decision support systems 
(discussed in Box 7) work best when patients as well as clinicians are given 
support. 
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Box 7: Clinical decision support systems might also reduce questionable care Figure 17: Most studies show the systems improve 
treatment choice 
Notes: OR of recommended 
treatments, by study age (1976 at 
top, 2010 at bottom).  
Source: Lobach et al. (2012) 
Clinical decision support systems give tailored assessments or recommendations to help diagnose or treat a 
patient. By doing this, they can make clinical evidence and guidance relevant and easy to access.  
There are many types of clinical decision support systems. A computer program could summarise evidence 
and recommend treatments. An alert might tell a doctor that a test for a patient with diabetes is due. A warning 
could say that a test or drug isn’t recommended for a patient, perhaps because of other drugs he or she takes 
or particular health problems.62 These systems can help ensure that the vast, constantly evolving evidence that 
underpins good care isn’t overlooked. Most studies (52 to 68 per cent) have found that decision support 
systems improve clinician performance.63 In particular, across a range of health care settings there is good 
evidence that these systems lead to the recommended treatment being ordered or prescribed more often.64  
The systems don’t always work, but they are developing quickly and evidence is emerging about how to make 
them work better. They perform best when they are integrated into workflow at the point of care, when they 
provide active recommendations (not just assessments),65 when clinicians must enter a reason for overriding 
advice, and when they also give advice to patients.66 
Clinical decision support systems show great promise and can improve further, but there is not yet clear 
evidence they will be cost-effective.67 It is worth local hospital networks and Primary Health Networks testing 
these systems. Once we have more local evidence about making them work well, the case for rolling them out 
more widely is likely to be strong. 
                                            
62 Other forms include care summary dashboards, which bring together important information about a patient in one place so that it is not overlooked. 
63 These figures are from a series of meta-reviews: Garg, et al. (2005); Kawamoto, et al. (2005); Main, et al. (2010); Lobach, et al. (2012); Roshanov, et al. (2013). There 
are few findings of improved patient outcomes, but these may take time to emerge after improved adherence to guidelines. 
64 A meta-analysis evaluating both electronic clinician decision support and knowledge management systems (the latter selectively retrieves information relevant to a 
specific patient), found recommended orders/treatments were more likely to be ordered with these systems (OR 1.57; CI 1.35-1.82). The review found that the quality of 
the evidence was strong, Lobach, et al. (2012). 
65 Kawamoto, et al. (2005) 
66 Based on a meta-regression of randomised trials, Roshanov, et al. (2013). Advice being automatic may also be beneficial (OR 1.48; CI 0.62-3.52). 
67 Black, et al. (2011) 
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6. Tackling poor performance
Even with clear definitions and better information about variation, 
pockets of poor performance will persist. The response should be 
to find out where the wrong treatments are being chosen and put 
a stop to them. 
There are currently many attempts to evaluate the quality of care 
but they rarely focus on the choice of treatment and few impose 
consequences on hospitals or individual doctors (see Box 8 for 
some examples). 
The information outlined in the previous chapter can be used to 
improve many mechanisms such as those in Box 8. In particular, 
it can be used in accreditation of hospitals and their training 
programs, in state oversight of hospitals, and in day-to-day 
hospital management. 
We found that questionable care is highly concentrated, not just in 
individual hospitals but in individual departments. Many standard 
approaches to improving quality, such as accreditation of an 
entire hospital, are too broad to pick up these problems. Others, 
while useful, might be too narrow and not linked to meaningful 
consequences. Clinical registries and Clinical Care Standards 
(see footnote for definitions) fall into this group.68 
Few existing approaches combine rigorous measurement of 
variation in clinical choices with explicit consequences for health 
                                            
68 Clinical registries are detailed datasets about patients receiving a specific 
type, or types of treatment. Clinical Care Standards will set out best practices for 
treating a small number of specific conditions (such as acute coronary 
syndrome). Consultation is under way for four, Australian Commission on Safety 
and Quality in Health Care (2014). 
care providers.69 To fill the gap, we recommend using data to 
manage outliers much more clearly and actively. But this should 
only happen following expert clinical evaluation to verify that a 
hospital is choosing inappropriate treatments. The process should 
proceed as described below. 
6.1 Clinical reviews and clear consequences 
Outlier health providers should be identified using Australian 
Commission on Safety and Quality in Health Care data. They 
should be told that their patterns of care are unusual, and given a 
chance to change.  
If they remain outliers, an external clinical review should check 
whether there is a good reason and why. A review might find that 
a hospital treats extremely rare cases from across Australia, or 
that the treatments were part of a clinical trial, for example. It 
might then conclude that the hospital had good reasons for its 
unusual treatment choices.  
The reviews should target the parts of a hospital (they might be 
specific specialties, such as obstetrics or oncology) that choose 
the relevant procedure. The review should be done by a team with 
relevant clinical expertise. It could use patient records, other 
hospital data, interviews and observation to understand the needs 
of the hospital’s patients and how they are treated.   
                                            
69 Some types of Medicare Benefits Scheme and Pharmaceutical Benefits 
Scheme audits are an exception, see Box 8 and Department of Human Services 
(2014) for more information. 
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Box 8: Some ways that quality is evaluated at present: 
Hospital accreditation – Hospitals must be accredited using 
agreed national standards that focus on safety and governance.70  
Training accreditation – Medical colleges accredit hospitals to 
train doctors in a specialty (such as surgery). 
Notifications about doctors – The Medical Board of Australia 
investigates notifications and complains about doctors, which can 
result in medical registration being revoked. 
Hospital management – Hospitals have internal processes to 
monitor and review performance. States also monitor various 
quality measures and may intervene to manage poor 
performers.71 
Registries – For specific procedures (such as hip replacements), 
or patient groups, clinical registries collect detailed information 
about patients, treatments and outcomes.  
Medicare and PBS audits – The Department of Human Services 
identifies suspicious practices through Medicare and 
pharmaceutical billing data. Due to the limited information about 
patients’ health needs, it focuses mostly on consultation type and 
frequency rather than treatment choice.  
                                            
70 The Australian Commission on Safety and Quality in Health Care developed 
the standards, but accreditation is done by internationally recognised bodies. 
71 One measure of quality is the rate of adverse events (preventable conditions 
developed in hospital). For further discussion of public hospital governance see 
Duckett, et al. (2014). 
State health departments should organise the reviews, perhaps 
inviting medical colleges to help design and staff them. The 
reviews should extend to private as well as public hospitals, since 
states license the former and fund the latter. 
When external reviews find that a hospital is choosing the wrong 
treatments, it should be given concrete targets for improvement. A 
target could be to no longer provide do-not-do treatments, or to 
provide do-not-do-routinely procedures at a lower rate. 
A hospital that fails to meet these targets should face serious 
consequences. Public hospitals should have their funding cut for 
ineffective treatments, or face other monitoring and sanctions in 
the state’s graded governance system.72 
Private insurers should also have the option to withhold funding 
from these persistent outliers. This will require the Commonwealth 
to amend its legislation.73 Insurers could also notify their members 
about the risks of going to hospitals that have not improved after 
negative clinical review findings. 
Figure 18 shows our proposed approach. 
                                            
72 For a broader discussion of graded governance management, see ibid. 
73 Legislation (Commonwealth of Australia (2007)) should allow insurers not to 
pay for care in hospitals that the HPPC identifies as outliers, provided that 
external clinical reviews do not support the relevant clinical practices.  
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 Figure 18: How to evaluate and manage outliers 
 
Source: Grattan Institute 
For outlier hospitals that do not improve, clinical evaluation must 
precede any funding or management change. Immediately cutting 
funding or other sanctions would be simpler, but is risky, for two 
reasons.  
First, cuts could penalise variation that is legitimate. A hospital 
might specialise in rare and complex patients, resulting in unusual 
treatment patterns. Without a clinical review, the legitimate reason 
for variation would not come to light. 
Second, cuts could lead to gaming. If there is a simple formula for 
funding cuts, clinicians might just change their reporting to get 
around it.74 Finally, cuts are likely to alienate clinicians. Health 
care professionals are more likely to respond to evaluations of 
quality by their peers than a financial sanction based on data 
alone.75 
 
                                            
74 This may have happened in the US after Medicare de-funded knee 
arthroscopy for osteoarthritis (one of our do-not-dos). While the number of 
reported knee arthroscopies for osteoarthritis went down, the overall number of 
knee arthroscopies increased. It is not clear if this was due to changes in 
treatment choice, or merely changes in coding. See Katz, et al. (2014). 
75 For a discussion of ‘policy alienation’ (where professionals who regularly 
interact with clients resist policy change due to disconnection from its 
development, implementation and/or objectives) see Tummers (2011); Tummers 
(2013). Our recommendations also reflect the view that health care regulation 
should be flexible and should seek to enhance, not replace, social cohesiveness, 
Chinitz (2002). 
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Figure 19: Types of quality assurance - where the proposed clinical 
reviews fit in 
 
Source: Adapted from Scrivens (2002) 
6.2 Identifying outliers 
Here we suggest some simple rules to identify outlier hospitals 
with troubling treatment patterns.   
Do-not-do treatments happen in about a fifth of public hospitals.76 
It makes sense to start with hospitals that provide them to a larger 
proportion of relevant patients – hospitals where there are most 
likely to be serious problems. Such an approach will also make 
                                            
76 Our data release agreement precludes our identifying the names of public 
hospitals. We also cannot identify the proportion of private hospitals where do-
not-do treatments occur because of the way the data were provided to us.  
sure that only a manageable number of hospitals are being 
monitored. 
All hospitals with an above-average rate of a do-not-do treatment 
should be considered outliers. Rates above zero but below the 
average are still a concern, but they could be due to data errors, 
or to using a do-not-do treatment as a last resort in very rare 
cases.  
For treatments that should not be done routinely, more variation is 
legitimate. For these treatments, only hospitals that deviate 
greatly from normal patterns of care should be considered 
outliers. We suggest that only the 10 per cent of hospitals that are 
most likely to provide do-not-do routinely treatments be 
considered outliers.77  
Based on these benchmarks, 126 hospital departments would be 
identified as outliers (Figure 20). The most in any one state is 33 
in Victoria, followed by 25 in NSW (Figure 21). The figure would 
rise when more treatments were monitored (see Chapter 7). 
However, many hospitals would adopt more normal patterns of 
care once they were told they were outliers. The remainder might 
need a clinical review to look into the quality of care.  
                                            
77 As explained above, these rates are only compared among hospitals that 
provide the relevant procedure and treat the relevant type of patient. Any outlier 
measure should be used with caution. For example, in the unlikely case of a do-
not-do-routinely treatment with almost no variation in hospital treatment rates, 
outliers should not be selected using this rule (they would be very close to 
normal treatment patterns). 
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Figure 20: Do-not-do treatments (top) should have a different 
benchmark for do-not-do routinely treatments (bottom)  
Hospital departments that are above the benchmark 
 
              Do-not-do benchmark options: multiples of the average rate 
 
Hospital departments that are above the benchmark 
Source: Grattan Institute analysis of NHMD 
Figure 21: There are at most 35 outlier hospitals in any one state 
Outlier hospitals 
Source: Grattan Institute analysis of NHMD 
Figure 22: Outliers are in regional Australia as well as cities 
Outlier hospitals 
Source: Grattan Institute analysis of NHMD 
0
50
100
150
200
250
300
0 1 2 3 4 5 6 7 8 9 10
Proposed benchmark: 1 times the national average
72 hospitals are above this level
All do-not-dos
0
200
400
600
Proposed benchmark: top 10% 
54 hospitals are above this level
Hospitals ranked by rate of do-not-do routinely
Lowest Highest
Amniotomy
Episiotomy
Fundoplication
0
5
10
15
20
25
30
35
NSW VIC QLD WA SA TAS NT
Do-not do treatments
Do-not-do routinely treatments
Both
Reason for being an outlier:
0
10
20
30
40
50
Cities Inner
regional
Outer
regional
Remote Very remote
Do-not do treatments
Do-not-do routinely treatments
Both
Reason for being an outlier
Questionable care 
Grattan Institute 2015 32 
States are unlikely to launch clinical reviews for all do-not-do 
treatments, at least initially. Therefore they should put a priority on 
treatments and hospitals where more patients are affected, or 
where the procedure carries the greatest risk. 
Initially, the focus should be on the handful of hospitals that do the 
bulk of do-not-do treatments (Figure 23). Of the treatments we 
measure, 72 per cent happen in just three hospitals in Tasmania, 
Queensland and Western Australia.78  
Figure 23: Most do-not-do treatments we measured are 
concentrated in a small number of hospitals 
Cumulative share of do-not-do treatments 
 
Source: Grattan Institute analysis of NHMD 
                                            
78 Share of public hospital do-no-do procedures (hospital-level data were not 
available for private hospitals). 
Looking into these hospitals first will target the bulk of the 
questionable care we measured. In these hospitals where more 
patients are affected we can also be more confident that high 
rates of do-not-do treatments reflect problems in treatment 
choices. In these cases, a one-off mistake, or a few errors in data 
entry, cannot have a big impact on the results. 
Once hospitals with a high share of do-not-do treatments are 
reviewed, states should move on to other persistent outliers. This 
will be worthwhile even if they only do one or two such treatments 
a year. Failure to review these hospitals would leave people who 
visit smaller hospitals, especially in rural areas, with too little 
protection from inappropriate care. 
Clinical reviews would only happen after hospitals are given 
information on how they compare, outliers are warned and given 
opportunities to improve. This means there are likely to be far 
fewer than 126 clinical reviews a year for the eight treatments that 
we examined. If there were only 40 across the country, the cost 
would be low – perhaps $430,000 a year.79  
This figure may increase after more do-not-do treatments are 
identified and measured (see below). Yet some of the expenditure 
would probably be offset by reduced use of ineffective care. The 
rest would be a worthwhile investment in making sure that 
patients get the right treatment.  
  
                                            
79 Assumes no use of existing resources to carry out the reviews. See the 
methodological supplement for more information on this explanation of this cost 
estimate. 
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7. Measuring more and measuring better 
This report has discussed eight examples of do-not-do and do-
not-do-routinely treatments. But the problem of ineffective 
treatments is far larger. By using more data and drawing on more 
sources of guidance, the Australian Commission on Safety and 
Quality in Health Care can analyse more questionable care. 
7.1 Using more data 
We used a list of more than 1000 treatments, but could not 
measure most of them with the data we had. This shouldn’t stop 
the Commission, which should get all the major data sets on 
Medicare, medicines and hospital services.80 Using more data, 
the Commission will be able to measure more forms of 
questionable care. In the future, government can also collect new 
data, creating yet more opportunities to understand and improve 
health care. 
7.1.1 Linking patient records 
The Commission will be able to link patient records over time.81 It 
can also link patient records across different parts of the health 
system: hospitals, the Pharmaceutical Benefits Scheme and the 
Medicare Benefits Scheme.  
Linking will let the Commission understand what happens to a 
patient over time. This is critical, because few treatments are 
                                            
80 MBS and PBS data, the National Hospital Morbidity dataset and potentially 
clinical registry data. 
81 We could not do this, due to restrictions in our data access agreement.  
always inappropriate. Instead, appropriateness often depends on 
the patient’s medical and treatment history. An example is 
grommet surgeries in young children, which are inappropriate if 
antibiotics haven’t already been tried (see Box 9).  
As a bonus, understanding patient histories will mean the 
Commission can measure readmissions, letting them track 
questionable care more accurately.82 
In the 2015-16 Budget, the Government announced trials of opt-
out personal electronic health records. Currently people have to 
sign up and only a small minority of Australians have.83 If the trials 
find ways to increase uptake by clinicians as well as patients, and 
to promote complete and reliable electronic records, these 
records could be an invaluable way to identify questionable care. 
7.1.2 Including test results 
To allow more types of questionable care to be measured, the 
next step is to add the results of blood tests and imaging (such as 
x-rays or MRI scans) to hospital, Medicare and PBS data. These 
results are already communicated electronically to health care 
providers.  
                                            
82 We could not control for readmissions, so do-not-do rates are a percentage of 
hospital visits rather than the number of individual patients treated.  
83 Rollins (2014) 
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Box 9: Ineffective surgery for middle ear effusion in children 
Fluid in the middle ear is a common health condition, especially among children.  Delayed treatment was once thought to harm child 
development. Persistent cases were promptly treated with surgery that put a fluid-draining tube (a grommet) in the eardrum. But in 2001, 
new evidence showed that prompt surgical treatment had no developmental benefit for young children. Based on this evidence, surgery is 
considered inappropriate unless treatment with antibiotics has failed.84   
As Figure 27 shows, the rate of grommet surgeries in Australia 
did not change much after this evidence was released. The 
national average stayed about the same, and huge variation 
persisted between the state with the highest rate (South 
Australia) and the jurisdiction with the lowest rate (Northern 
Territory).  
We can’t know for sure whether those surgeries were 
inappropriate. Ear infections may have increased, or antibiotics 
may have proven ineffective more often, meaning the number of 
necessary surgeries was unchanged.  
But by linking hospital and PBS records, the Commission could 
check how often children had the surgery without trying an 
antibiotic first – a do-not-do treatment.85  
Using the approach in this report, the Commission could then find 
out if this happens more in some hospitals than in others, and 
which hospitals are outliers. By following the other 
recommendations in this report, the information could reduce 
expensive, risky and unnecessary surgeries on children. 
Figure 24: New evidence may not have affected grommet surgeries 
Grommet surgeries per 1000 children aged 0-4
 
 
Source: Grattan Institute analysis of MBS data 
                                            
84 Paradise, et al. (2001) 
85 This would work best if the patient’s disease and treatment were also recorded as part of PBS dispensing, as discussed above. 
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7.1.3 Tracking illnesses and treatments with Medicare and 
the PBS 
Even once data are linked and test results are added, a big blind-
spot will remain: health problems being treated outside hospitals. 
At present, when treatments are charged to the MBS or PBS, 
information about the patient’s gender and age are transmitted, 
but not his or her health conditions.  
Providing this information would do more than allow the 
Commission to identify questionable procedures, testing and 
prescribing. Governments would know more about health 
problems and how they are being treated. It would be easier to 
identify and respond to health trends and health disparities.  
Sending the information could be easy. About 95 per cent of 
primary care doctors already use electronic health records.86 
Information on patient diseases could be transmitted just as easily 
as making online claims for Medicare benefits. 
Despite this, gathering data about health problems outside 
hospitals is harder and more costly than the other two changes 
we propose. Health care providers will need to have an efficient, 
intuitive way to enter the data and may need training or financial 
incentives.87 As a longer-term and more complex change, we 
recommend a trial in two or three Primary Health Networks to 
make sure it is cost-effective. 
                                            
86 Commonwealth Fund (2012) 
87 As far as possible, this should standardise how illnesses and reasons for visits 
are recorded. 
By using and linking more data, the Commission will be able to 
investigate many more do-not-do treatments. With the data we 
used for this report, an eighth of recent do-not-do guidelines from 
the UK’s NICE can be measured.88 With all the other data sources 
we recommend in this chapter, the Commission could measure 
nearly half (Figure 25). 
Figure 25: The Australian Commission on Quality and Safety in 
Health Care can measure much more  
Do-not-do guidance that can be measured with different data sources 
 
Source: National Institute for Health and Care Excellence 
7.2 Using more sources of guidance 
We only looked at a few sources of do-not-do advice. The 
Commission can use many more. It should start with the low 
                                            
88 The National Centre for Health and Care Excellence. Our estimate is only 
based on the guidance released at the time of writing from January to October 
2014. 
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hanging fruit: do-not-do treatments identified in comparable 
countries. Bodies such as the UK’s NICE have developed large 
lists of ineffective care in consultation with clinical experts. The 
Commission can also go further by exploring other sources of 
evidence, such as the thousands of systematic reviews produced 
by the Cochrane Collaboration.89 
  
                                            
89 The Cochrane Collaboration has produced 6094 published reviews and 2357 
protocols to date, although some of these are reviews of clinical practises rather 
than specific treatments. 
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8. Conclusion
Each year, thousands of patients get treatments that cannot help 
them. The consequences are serious. Their original health 
problem remains and the intended cure might make them sicker.  
This report presents a plan to stop ineffective treatments. The first 
step is to provide clear, consistent and up-to-date guidance about 
which treatments do not work. The second step is to track these 
treatments and report on where they happen. 
National guidelines and reporting will not replace existing efforts 
to improve the quality of care. Instead, it will super-charge them, 
giving powerful new information to clinicians, managers, hospitals, 
medical colleges, insurers and state governments. 
Information will help, but will not be enough on its own. This report 
confirms that a minority of hospitals have serious problems. Some 
of them will need a strong impetus to improve.  
Expert clinical reviews should be targeted where they are most 
needed: at hospitals that provide questionable care more often 
than their peers do. If a clinical review finds that the wrong 
treatments are being chosen, and the hospital still fails to improve, 
funding for ineffective care should be withdrawn and the hospital’s 
management should be replaced. 
Questionable care can be measured. This report only looked at a 
few procedures, but still found very troubling results. With more 
resources, expertise and data, the Australian Commission on 
Quality and Safety in Health Care can extend the approach set 
out in this report much further. It can measure many more 
treatments that should not be done at all, or should not be done 
routinely. It can champion better measurement of care outside 
hospitals, so that our approach can spread to primary care. 
The Commission can bring together expert clinical guidance and 
sophisticated measurement of patterns of care across the system. 
Linking guidance and measurement will provide a far richer 
picture of what is happening to patients in Australia. 
In the future, the benefits will go far beyond finding treatments that 
should not be given. Marrying clinical expertise and evaluation of 
care can help improve the quality of care in other ways. It can 
illuminate gaps in access to care, show which treatments work 
best, and measure how good practices spread throughout the 
system. 
Today, patients turning up to some hospitals face an 
unacceptable risk of getting the wrong treatment. We cannot hope 
to stop this unless we clearly define, measure and investigate 
questionable care. If we do not, we will be failing patients, who 
deserve to get the care they need. 
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